EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo

Qingqing Li, Wanshu Li, Jie Chen, Hangjuan Lin, Cixia Zhou

PeerJ · 2025

DOI: 10.7717/peerj.19313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Qingqing Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China. Hauptthemen laut MEDLINE: Carvedilol, Diarylquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningbo Medical & Health Leading Academic Discipline Project, Ningbo Medical & Health Brand Discipline Project, APC: Traditional Chinese Medicine Pharmaceutical Center Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bedaquiline has recently been approved for the treatment of multidrug-resistant tuberculosis. Carvedilol is a cardiovascular medication extensively used in the treatment of heart failure and hypertension. In this study, Sprague-Dawley rats, rat liver microsomes (RLM), human liver microsomes (HLM), and recombinant human CYP3A4 were used to explore the effect of carvedilol on the metabolism of bedaquiline. Ultra-performance liquid chromatography-tandem mass spectrometry was used to facilitate the quantification of the analyte concentrations. In vitro, carvedilol did not exhibit time-dependent inhibition of bedaquiline, which aligns with the half-maximal inhibitory concentration (IC 50 ) shift results. The IC 50 values of carvedilol were 15.35 ± 0.43 µM in RLM, 7.55 ± 0.74 µM in HLM, and 0.79 ± 0.05 µM in CYP3A4. Besides, the inhibition type of carvedilol was found to be mixed, un-competitive, and mixed in RLM, HLM, and CYP3A4, respectively. In vivo , the co-administration of carvedilol with bedaquiline resulted in a significant increase in the area under the plasma concentration-time curve (AUC) (0 − t ) , AUC (0 − ∞), and C max of bedaquiline while decreasing its CL z/F . Lay summary : Carvedilol could inhibit the metabolism of bedaquiline in vitro and in vivo , with different mechanisms in different enzymatic reaction systems. Hence, caution should be exercised when combining bedaquiline with carvedilol.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarvedilolDiarylquinolinesAnimalsRats, Sprague-DawleyMicrosomes, LiverRatsHumansCytochrome P-450 CYP3AMaleDrug InteractionsTandem Mass Spectrometry

Stichwörter der Autor:innen

BedaquilineCarvedilolDrug–drug interactionsInhibition mechanismsUPLC-MS/MS

Substanzen

CarvedilolDiarylquinolinesbedaquilineCytochrome P-450 CYP3ACYP3A4 protein, human

Autor:innen und Institutionen

  • Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Förderung

  • Ningbo Medical & Health Leading Academic Discipline Project
  • Ningbo Medical & Health Brand Discipline Project
  • APC: Traditional Chinese Medicine Pharmaceutical Center Construction Project

Zitieren

APA

Li, Q., Li, W., Chen, J., Lin, H., & Zhou, C. (2025). Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo. PeerJ. https://doi.org/10.7717/peerj.19313

Vancouver

Li Q, Li W, Chen J, Lin H, Zhou C. Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo. PeerJ. 2025. doi:10.7717/peerj.19313

BibTeX
@article{Li2025,
  author = {Li, Qingqing and Li, Wanshu and Chen, Jie and Lin, Hangjuan and Zhou, Cixia},
  title = {Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.19313}
}
Kostenlos starten →